Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer's disease, progressive supranuclear palsy, and dementia with lewy bodies

Journal of Alzheimer's Disease

Volumn 51, Issue 4, 2016, Pages 1033-1043

  Barthélemy, Nicolas R ^a,b   Gabelle, Audrey ^b,c   Hirtz, Christophe ^b   Fenaille, François ^a   Sergeant, Nicolas ^d   Schraen Maschke, Susanna ^d   Vialaret, Jérôme ^b   Buée, Luc ^d   Junot, Christophe ^a   Becher, François ^a   Lehmann, Sylvain ^b,e  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b HÔPITAL SAINT ELOI   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

^d UNIV LILLE   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Cerebrospinal fluid; mass spectrometry; neurodegenerative disease; tau protein

Indexed keywords

TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; AGED; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MENTAL HEALTH; METABOLISM; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STATISTICS AS TOPIC; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 84964917095     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150962     Document Type: Article

References (36)

1. Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, Buee L (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 5, 207 - 224.
2. Avila J, Lucas JJ, Perez M, Hernandez F (2004) Role of tau protein in both physiological and pathological conditions.∗Physiol Rev 84, 361 - 384.
3. Jack CR Jr, Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron 80, 1347 - 1358.
4. Giacobini E, Gold G (2013) Alzheimer disease therapy-moving from amyloid-beta to tau. Nat Rev Neurol 9, 677 - 686.
5. Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H (2014) Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: Results from the Swedish Mortality Registry. JAMA Neurol 71, 476 - 483.
6. Bombois S, Duhamel A, Salleron J, Deramecourt V, Mackowiak MA, Deken V, Sergeant N, Pasquier F, Buee L, Sablonniere B, Schraen-Maschke S (2013) A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer's diagnosis.∗Curr Alzheimer Res 10, 357 - 364.
7. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM (2011) Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68, 1137 - 1144.
8. Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, Bombois S, Bousiges O, Campion D, Cretin B, Delaby C, Hannequin D, Jung B, Hugon J, Laplanche JL, Miguet-Alfonsi C, Peoc'h K, Philippi N, Quillard-Muraine M, Sablonniere B, Touchon J, Vercruysse O, Paquet C, Pasquier F, Gabelle A (2014) A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther 6, 38.
9. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605 - 613.
10. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.Neurology 78, 47 - 54.
11. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297, 187 - 190.
12. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, Anderton BH (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.J Biol Chem 282, 23645 - 23654.
13. Funk KE, Thomas SN, Schafer KN, Cooper GL, Liao Z, Clark DJ, Yang AJ, Kuret J (2014) Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J 462, 77 - 88.
14. Lehmann S, Hoofnagle A, Hochstrasser D, Brede C, Glueckmann M, Cocho JA, Ceglarek U, Lenz C, Vialaret J, Scherl A, Hirtz C (2013) Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: General characteristics and application. Clin Chem Lab Med 51, 919 - 935.
15. Jaquinod M, Trauchessec M, Huillet C, Louwagie M, Lebert D, Picard G, Adrait A, Dupuis A, Garin J, Brun V, Bruley C (2012) Mass spectrometry-based absolute protein quantification: PSAQ strategy makes use of "noncanonical" proteotypic peptides.∗Proteomics 12, 1217 - 1221.
16. Picard G, Lebert D, Louwagie M, Adrait A, Huillet C, Vandenesch F, Bruley C, Garin J, Jaquinod M, Brun V (2012) PSAQ standards for accurate MS-based quantification of proteins: From the concept to biomedical applications.J Mass Spectrom 47, 1353 - 1363.
17. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: A Frontal Assessment Battery at bedside.Neurology 55, 1621 - 1626.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.Neurology 34, 939 - 944.
19. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop.Neurology 47, 1 - 9.
20. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium.Neurology 65, 1863 - 1872.
21. Lippens G, Wieruszeski JM, Leroy A, Smet C, Sillen A, Buee L, Landrieu I (2004) Proline-directed random-coil chemical shift values as a tool for the NMR assignment of the tau phosphorylation sites.∗Chembiochem 5, 73 - 78.
22. Bros P, Vialaret J, Barthelemy N, Delatour V, Gabelle A, Lehmann S, Hirtz C (2015) Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry.∗Front Neurosci 9, 302.
23. Peterson AC, Russell JD, Bailey DJ, Westphall MS, Coon JJ (2012) Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. MolCell Proteomics 11, 1475 - 1488.
24. Gallien S, Duriez E, Demeure K, Domon B (2013) Selectivity of LC-MS/MS analysis: Implication for proteomics experiments.J Proteomics 81, 148 - 158.
25. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc'h K, Schraen S, Buee L, Pasquier F, Hugon J, Touchon J, Lehmann S (2013) Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: The PLM Study.J Alzheimers Dis 34, 297 - 305.
26. Delaby C, Vialaret J, Bros P, Gabelle A, Lefebvre T, Puy H, Hirtz C, Lehmann S (2014) Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?.∗EuPA Open Proteomics 3, 60 - 67.
27. McAvoy T, Lassman ME, Spellman DS, Ke Z, Howell BJ, Wong O, Zhu L, Tanen M, Struyk A, Laterza OF (2014) Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin Chem 60, 683 - 689.
28. Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, Hoglund K, Brinkmalm G, Westman-Brinkmalm A, Nordhoff E, Blennow K, Gobom J (2008) Characterization of tau in cerebrospinal fluid using mass spectrometry.J Proteome Res 7, 2114 - 2120.
29. Greco V, Pieragostino D, Piras C, Aebersold R, Wiltfang J, Caltagirone C, Bernardini S, Urbani A (2014) Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples.∗Proteomics 14, 1954 - 1962.
30. Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF (2013) Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS One 8,.e76523.
31. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11, 909 - 913.
32. Lehmann S, Barthelemy N, Vialaret J, Schraen-Maschke S, Tiers L, Delaby C, Becher F, Touchon J, Junot C, Hirtz C, Gabelle A (2013) Quantitative mass spectrometry (SRM/MRM) for amyloid peptides, tau protein and apolipoprotein E in human cerebrospinal fluid for Alzheimer's disease diagnosis. Alzheimers Dement 4, 212.
33. D'Souza I, Schellenberg GD (2005) Regulation of tau isoform expression and dementia. Biochim Biophys Acta 1739, 104 - 115.
34. Sergeant N, Delacourte A, Buee L (2005) Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739, 179 - 197.
35. Luk C, Compta Y, Magdalinou N, Marti MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B, Trenkwalder C, Van Swieten J, Chiu WZ, Borroni B, Camara A, Cheshire P, Williams DR, Lees AJ, de Silva R (2012) Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies.J Neurochem 123, 396 - 405.
36. Domanski D, Murphy LC, Borchers CH (2010) Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: Application to breast cancer signaling pathways.∗Anal Chem 82, 5610 - 5620.